Galapagos Publishes 2025 Annual Report and Announces Annual and Extraordinary Shareholders’ Meetings

Core Viewpoint - Galapagos NV has published its annual report for the financial year 2025 and announced the scheduling of its Annual Shareholders' Meeting (AGM) and an Extraordinary Shareholders' Meeting (EGM) on April 28, 2026 [1][2] Financial Report - The annual report for the financial year 2025, including a review of figures and performance, is available online and can be downloaded as a PDF [1] - The annual 2025 Form 20-F filing with the SEC is accessible at the SEC's website [1] Shareholders' Meetings - The AGM will take place at 14:00 CET, followed by the EGM at 15:00 CET on April 28, 2026, at Schaliënhoevedreef 20T, 2800 Mechelen, Belgium [2] - The agenda for the AGM includes the appointment of Henry Gosebruch as executive director and several independent non-executive directors, as well as the re-appointment of BDO Bedrijfsrevisoren as the statutory auditor [3] - The EGM agenda includes a proposed name change to Lakefront Biotherapeutics, authorization for share repurchase of up to 10% of outstanding shares, and renewal of the Board's authorization to increase share capital [4] Compliance and Documentation - To attend the AGM and EGM, holders of securities must comply with specific articles of the Belgian Code of Companies and Associations and fulfill formalities described in the convening notice [5] - Additional documents related to the meetings, including biographies of proposed directors, are available on the company's website [5] Company Overview - Galapagos is a biotechnology company focused on developing meaningful medicines for patients with serious diseases, prioritizing oncology and immunology & inflammation programs [6]